The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index; 81 of the 118 sources its claims cite were checked for support.
The promise and challenge of therapeutic genome editing
Open accessAbstract
Genome editing, which involves the precise manipulation of cellular DNA sequences to alter cell fates and organism traits, has the potential to both improve our understanding of human genetics and cure genetic disease. Here I discuss the scientific, technical and ethical aspects of using CRISPR (clustered regularly interspaced short palindromic repeats) technology for therapeutic applications in humans, focusing on specific examples that highlight both opportunities and challenges. Genome editing is—or will soon be—in the clinic for several diseases, with more applications under development. The rapid pace of the field demands active efforts to ensure that this breakthrough technology is used responsibly to treat, cure and prevent genetic disease. The scientific, technical and ethical aspects of using CRISPR technology for therapeutic applications in humans are discussed, highlighting both opportunities and challenges of this technology to treat, cure and prevent genetic disease.
Overview
CoChat Summary
TL;DR
This review argues that therapeutic genome editing, especially CRISPR-Cas9, is moving toward the clinic for some monogenic diseases but still faces major delivery, precision, safety, cost, and governance challenges. It contrasts somatic editing with heritable germline editing and calls for responsible, regulated use.
Key findings
- Monogenic diseases are a major target: ~5,000 are known and affect at least 250 million individuals. Sickle cell disease, caused by a single A-to-T mutation in β-globin, could be treated ex vivo by correcting the mutation in hematopoietic stem/progenitor cells or reactivating γ-globin; ~100,000 US patients and millions more in African and Asian countries are potential candidates.
- Duchenne muscular dystrophy affects one in 5,000 males at birth and can involve >3,000 mutations, mostly at hotspots; restoring ~15% of normal dystrophin expression may provide clinical benefit. In animal studies, systemic AAV CRISPR delivery restored up to 90% dystrophin in ΔEx50 mice, and in dogs dystrophin levels were restored to 3–90% of normal with improved muscle appearance.
- Delivery is a central bottleneck: ex vivo editing favors electroporation of Cas9 ribonucleoprotein complexes, while in vivo delivery uses viral vectors such as AAV or lipid nanoparticles. AAV can carry only ~4.7 kb, not much larger than the 4.2 kb SpCas9 gene, so corrective insertion often requires two AAV vectors.
- Safety and governance concerns include off-target and imprecise editing, rare large deletions and complex rearrangements, possible immunogenicity from pre-existing Cas9 antibodies/T cells, and unresolved long-term safety. For germline editing, the paper states it is inappropriate to perform editing that culminates in human pregnancy at this time, while in vitro embryo/gamete research should be allowed with oversight.
Methods
- Narrative review by Jennifer A. Doudna; no systematic search strategy, primary dataset, or new experimental results are reported.
- Synthesizes CRISPR-Cas therapeutic genome editing, including sickle cell disease and DMD examples, delivery modalities, accuracy/safety issues, clinical development, and ethical/regulatory discussion of somatic versus germline editing.
- Draws on cited animal studies, early clinical trials, and international scientific/organizational positions; no sample size or formal analysis is stated in the paper.
Limitations
- Stated: delivery remains perhaps the biggest bottleneck to somatic genome editing; AAV has packaging, immunogenicity, and scalable GMP production/cost challenges, while lipid nanoparticles can be toxic and cell-type selective.
- Stated: off-target and imprecise editing, large deletions, and complex rearrangements occur at low frequency but could be clinically significant; immunogenicity and long-term safety/efficacy of edited cells in vivo remain largely unknown.
- Stated and evident: germline editing raises unresolved scientific questions about DNA repair in early human embryos and ethical/policy questions; as a review, the paper provides no new primary data and relies on cited studies and early-stage clinical information.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
40 Valid · 10 Not valid · 12 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Engineered DNA-cleaving enzymes including zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) demonstrated the promise of therapeutic genome editing.”
What the sources say
- Not checked — no full text of the sourcecites [16] Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143–148 (2011). source
- Not checked — no full text of the sourcecites [17] Hoban, M. D. et al. Zinc finger nucleases targeting the β-globin locus drive efficient correction of the sickle mutation in CD34+ cells. Blood 122, 2904 (2013). source
- Partly supportedcites [18] Chang, K.-H. et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34+ hematopoietic stem and progenitor cells. Mol. Ther. Methods Clin. Dev. 4, 137–148 (2017). sourceExperimental — accuracy not yet measured
The Results and Discussion describe ZFN-mediated BCL11A editing and call it a strong preclinical proof of concept for a potential sickle-cell therapy. The cited paper does not report a comparable demonstration using TALENs, so it supports the claim for ZFNs but not for both named enzyme types. (LLM, conf=0.88)
- Partly supportedcites [19] Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017). sourceExperimental — accuracy not yet measured
The Introduction reports first-in-human use of TALEN-edited T cells, and the Discussion says this application demonstrates the potential of gene-editing strategies for engineered cell therapies. The paper supports the claim about TALENs, but the passages do not establish the same point for ZFNs. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, restoration of a small percentage (~15%) of normal dystrophin expression levels can provide a clinical benefit 15 .”
What the sources say
- Partly supportedcites [15] Long, C. et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184–1188 (2014). sourceExperimental — accuracy not yet measured
The supplied passages (labeled Abstract; page unavailable) report that correcting 17% of mutant Dmd alleles in mice restored dystrophin in many muscle fibers and reduced dystrophic features. They do not show that dystrophin expression was restored to ~15% of normal levels: 17% refers to gene correction, not protein expression. The reported benefits are in mice, not a demonstrated clinical benefit in patients. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cas9 protein-sgRNA complexes can be incorporated by assembly with DNA-linked particles 78,79 .”
What the sources say
- Partly supportedcites [78] Glass, Z., Li, Y. & Xu, Q. Nanoparticles for CRISPR–Cas9 delivery. Nat. Biomed. Eng. 1, 854–855 (2017). sourceExperimental — accuracy not yet measured
The formulation passage (Abstract; page not provided) describes a gold nanoparticle core surrounded by a Cas9–gRNA complex and a DNA repair template. This supports incorporating the complex into a particle, but the copy does not specify assembly with DNA-linked particles. (LLM, conf=0.80)
- Supportedcites [79] Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017). source
The Results and discussion section (‘Design and synthesis of CRISPR-Gold’; page unavailable) says donor DNA is attached to gold nanoparticles and Cas9 ribonucleoprotein is then adsorbed onto them. The Methods section (‘S5. Synthesis of CRISPR-Gold’; page unavailable) specifies that Cas9 and guide RNA are mixed before being added to the DNA-linked particles. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In cells of all multicellular organisms, including humans, such double-stranded DNA breaks induce DNA repair by endogenous cellular pathways that can introduce alterations to the DNA sequence, including small sequence changes or genetic insertions 21,22 .”
What the sources say
- Not checked — no full text of the sourcecites [21] Szostak, J. W., Orr-Weaver, T. L., Rothstein, R. J. & Stahl, F. W. The double-strand-break repair model for recombination. Cell 33, 25–35 (1983). The authors proposed a surprising but ultimately correct cellular DNA repair mechanism in which double-stranded breaks are enlarged to double-stranded gaps to initiate genetic recombination, forming the basis for genome editing mediated by DNA repair. source
- Partly supportedcites [22] Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol. 24, 9305–9316 (2004). Double-stranded DNA breaks in mammalian cells trigger DNA repair that can introduce site-specific changes in the genome sequence. sourceExperimental — accuracy not yet measured
The Abstract (page not provided) says that mammalian cells repair double-strand breaks through pathways that can cause deletions or insertions at the break site. It also discusses mutagenic repair associated with human disease. The paper does not establish that this applies to cells of all multicellular organisms, so the claim extends beyond its stated scope. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Alternatives to DNA cleavage-induced editing include using CRISPR-Cas9 for direct chemical sequence alteration (base editing) 25,26 , providing RNA templates for gene alteration (prime editing) 27,28 , and for transcriptional control (CRISPR interference, CRISPRi; CRISPR activation, CRISPRa) 29,30 (Fig. 3).”
What the sources say
- Supportedcites [25] Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016). A DNA-nicking version of CRISPR–Cas9 was fused to a DNA-editing enzyme that enables targeted nucleotide changes to be introduced at Cas9-directed genome locations. sourceExperimental — accuracy not yet measured
The Abstract describes a CRISPR/Cas9-based editor that directly converts a target DNA base without a double-stranded break or donor template. This supports the base-editing clause to which this citation is attached; the prime-editing and CRISPRi/CRISPRa clauses have separate citations. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [26] Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016). CRISPR–Cas9 was fused to a DNA-editing enzyme that enables targeted nucleotide editing at genome locations recognized by Cas9, while avoiding double-stranded DNA breaks. source
- Could not verifycites [27] Sharon, E. et al. Functional genetic variants revealed by massively parallel precise genome editing. Cell 175, 544–557 (2018). This study showed that an RNA template can be used together with a Cas9–reverse transcriptase fusion protein to introduce small targeted changes in cellular genomes without involving double-stranded DNA break repair. sourceExperimental — accuracy not yet measured
The citation is attached to the sentence’s claim about CRISPRi/CRISPRa for transcriptional control. The Introduction and Results describe Cas9 cleavage followed by donor-directed repair, not CRISPRi or CRISPRa; searches for those terms and transcriptional control found no passage addressing that claim. The References mention base editing, but do not establish the claim for which this citation is offered. (LLM, conf=0.75)
- Supportedcites [28] Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019). A CRISPR–Cas9-reverse transcriptase fusion protein was used together with extended guide-RNA templates to introduce small sequence changes within approximately 50 base pairs of the location of Cas9 binding. sourceExperimental — accuracy not yet measured
The citation is attached to the prime-editing part of the sentence, not the claims about base editing or CRISPRi/CRISPRa. The Abstract and “Prime editing strategy” section describe an edit-encoding RNA guide whose information is copied into target DNA without a double-strand break or donor DNA template. (LLM, conf=0.93)
- Supportedcites [29] Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013). This study demonstrated the use of a catalytically deactivated form of CRISPR–Cas9 for transcriptional control in cells. source
The citation is attached to the transcriptional-control portion of the sentence, not the base- or prime-editing examples. In “CRISPRi as a Platform for Engineering Transcriptional Regulatory Networks” (page not provided), the paper describes CRISPRi as a dCas9-based approach to targeted gene regulation, including transcriptional repression and potential activation, without altering the target sequence. (LLM, conf=0.92)
- Supportedcites [30] Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647–661 (2014). sourceExperimental — accuracy not yet measured
The citation is attached to the transcriptional-control part of the sentence, not to base or prime editing. The Introduction (page not supplied) describes the use of CRISPRi to repress and CRISPRa to activate transcription, and reports applying both methods to control gene expression. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
45 more claims · 23 with their cited sources checked
Create a free account to see all 98 claims and every source verdict.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR-Cas dominates the field because of the ease of using guide RNAs directing the CRISPR complex to specific DNA sequences and the increasing ability to target most sites in the genome.121,122”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [121]
Experimental — accuracy not yet measured
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Self-citationMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Self-citationSearch-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Self-citationGasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728
Cited by
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03534-y · Cited by 793
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668
“Recently developed gene editing agents enable the precise manipulation of genomic DNA in living organisms and raise the possibility of treating the root cause of many genetic diseases (Anzalone et al., 2020; Doudna, 2020; Newby and Liu, 2021).”
BackgroundPast, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
“39,88,92 Cas9/Cas12a enzymes and their guide RNAs can be delivered in multiple formats, depending on the target cell type or organism.”
Anzalone, A. V., Gao, X. D., Podracky, C. J., Nelson, A. T., Koblan, L. W., Raguram, A., Levy, J. M., Mercer, J. A. M., & Liu, D. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01133-w · Cited by 613
Metadata
- Authors
- Doudna, J. A.
- Affiliations
- QB3 (US)
- Corresponding author
- Doudna, Jennifer A.
- ORCID
- Doudna, Jennifer A.
- Venue
- Nature
- Published
- 2020-02-12
- Volume
- 578
- Issue
- 7794
- Pages
- 229-236
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8992613
- OpenAlex
- W3006116138
- Semantic Scholar
- 58b8496f86ab37bb66e32f96f5492f531b5ca37b
- Cited by
- 1,126
- References
- 160
- Citations by year
- 2026: 123 · 2025: 169 · 2024: 184 · 2023: 259 · 2022: 173 · 2021: 144 · 2020: 73
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Science Foundation (1817593)
- Howard Hughes Medical Institute
- W. M. Keck Foundation
- Innovative Genomics Institute
- Multiple Sclerosis Society
- National Institutes of Health
- Defense Advanced Research Projects Agency (HR0011- 17-2-0043)
- Advanced Research Projects Agency
- National Human Genome Research Institute (RM1HG009490)
- National Institute of Allergy and Infectious Diseases (U01AI142817)
- Common Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- therapeutic genome editing, CRISPR, genetic disorders, gene therapy, ethics of gene editing, precision genome editing, clinical translation
- MeSH terms
- Gene Editing, Anemia, Sickle Cell, Humans, Organ Specificity, Genome, Human, Germ-Line Mutation, Muscular Dystrophy, Duchenne, beta-Globins, Patient Safety, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The promise and challenge of therapeutic genome editing. https://app.cochat.ai/papers/10.1038/s41586-020-1978-5
- The paper
- Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature. https://doi.org/10.1038/s41586-020-1978-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.




